Letter to COVID-19 Vaccine Manufacturers

On July 13th, HHS released a letter directed to COVID-19 manufacturers regarding the transition of vaccines to more traditional pathways and the upcoming 2023-2024 COVID-19 vaccination campaign. The letter states that HHS expects vaccines will remain available following the transition in current locations, such as pharmacies and clinics, and priced at reasonable rates. HHS expects vaccine manufacturers that plan to offer the updated COVID-19 vaccines prepare a sufficient supply of doses for the upcoming vaccination campaign...